← Eichor
Study identifier: NCT06123884 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer

Condition: Cervical Cancer  ·  Sponsor: Bio-Thera Solutions

PhasePhase 2/Phase 3
Planned participants526
Who can joinFemale, 18 Years to 70 Years
Healthy volunteersNo

About this study

Phase II study: a study to explore the safety and preliminary efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab Phase III study: a confirmatory study to evaluate the safety and efficacy of BAT1308 combined with platinum-based chemotherapy ± Bevacizumab as first-line therapy for PD-L1-positive (CPS ≥ 1) persistent, recurrent or metastatic cervical cancer

This description comes directly from the study's public registry record.

Talk to the study team

Juan Chen  ·  18971436492  ·  jchen@bio-thera.com

Zhaohe Wang, Ph.D

Always discuss trial participation with your own doctor first.

Locations (1)

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & TechnologyWuhan, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06123884